.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB01_Glibenclamide.Glibenclamide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB01_Glibenclamide.Glibenclamide| name: | Glibenclamide |
| ATC code: | A10BB01 | route: | oral |
| n-compartments | 2 |
Glibenclamide (also known as glyburide) is a second-generation sulfonylurea used for the treatment of type 2 diabetes mellitus. It stimulates insulin secretion from pancreatic beta cells. Glibenclamide is widely approved and marketed for this indication globally.
Pharmacokinetics in healthy adult volunteers, after single oral administration, sexes combined.
Bouazza, N, et al., & Polak, M (2016). Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia. European journal of clinical pharmacology 72(11) 1373–1379. DOI:10.1007/s00228-016-2119-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27561267
Jönsson, A, et al., & Melander, A (2000). Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. European journal of clinical pharmacology 56(9-10) 711–714. DOI:10.1007/s002280000214 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11214781
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821